ArticleEuropean heart journal open2026
Long-term outcomes after septal reduction therapy for obstructive hypertrophic cardiomyopathy: a nationwide cohort study.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Authors' response: septal reduction therapy for obstructive hypertrophic cardiomyopathy.European heart journal open · 2026Article
- Septal reduction therapy in obstructive hypertrophic cardiomyopathy: contextualizing outcomes in an era of cardiac myosin inhibition.European heart journal open · 2026Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: With cardiac myosin inhibitors emerging as a novel pharmacological option instead of septal reduction therapies (SRT) in obstructive hypertrophic cardiomyopathy (HCM), contemporary data on national long-term outcomes after SRT are needed. Methods and results: In this nationwide cohort study from 2015 to 2021, patients with obstructive HCM undergoing SRT (surgical myectomy or transcoronary ablation of septal hypertrophy) were 1:8 propensity score-matched with non-obstructive HCM patients or surgical controls undergoing appendectomy without heart disease in recent records. As assessed in time-to-event analyses, the primary outcome was a composite of all-cause mortality after discharge and rehospitalization for heart failure. After matching, 125 patients with obstructive HCM hospitalized for SRT were compared to 743 patients hospitalized with non-obstructive HCM. The incidence rate (IR) of the primary outcome was lower in the SRT group {12.62 vs. 74.86 per 1000 patient-years (py); hazard ratio (HR), 0.17 [95% confidence interval (CI), 0.07-0.42]; median follow-up 31 months}. In the second comparison, 126 patients with obstructive HCM undergoing SRT were matched to 560 surgical controls without heart disease undergoing laparoscopic appendectomy. The IR of the primary outcome after SRT was comparable to that of surgical controls without heart disease [12.61 vs. 8.09 per 1000 py; HR, 1.53 (95% CI, 0.56-4.18); median follow-up 41 months]. Conclusion: In this nationwide cohort study, SRT was associated with a lower incidence of all-cause mortality after discharge and rehospitalization for heart failure compared to patients hospitalized with non-obstructive HCM, with an incidence comparable to surgical controls without heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.